Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.

David ElseaKerry J SavageCameron LilleyJulie LisanoJingmin LiuKristina S Yu

Published in: Advances in therapy (2023)

Brentuximab vedotin compared with MTX or BEX was cost-effective for CD30-expressing MF and pcALCL. Brentuximab vedotin's higher drug costs versus MTX or BEX were offset by decreased post-progression and end-stage management costs, and showed a 0.25 QALY gain versus MTX or BEX, and increased the proportion of patients eligible for potentially curative SCT.

Keyphrases

hodgkin lymphoma
end stage renal disease
prognostic factors
newly diagnosed
ejection fraction
primary care
emergency department
chronic kidney disease
low dose
rectal cancer